NO20044903L - Anvendelse av nye etonogestrel estere - Google Patents

Anvendelse av nye etonogestrel estere

Info

Publication number
NO20044903L
NO20044903L NO20044903A NO20044903A NO20044903L NO 20044903 L NO20044903 L NO 20044903L NO 20044903 A NO20044903 A NO 20044903A NO 20044903 A NO20044903 A NO 20044903A NO 20044903 L NO20044903 L NO 20044903L
Authority
NO
Norway
Prior art keywords
new
etonogestrel esters
contraceptive
esters
new etonogestrel
Prior art date
Application number
NO20044903A
Other languages
English (en)
Norwegian (no)
Inventor
Hendrikus Adrianus Anton Voort
Dirk Leysen
Arij Jan Grootenhuis
Henrik De Nijs
Jaap Van Der Louw
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20044903L publication Critical patent/NO20044903L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20044903A 2002-05-30 2004-11-10 Anvendelse av nye etonogestrel estere NO20044903L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30
PCT/EP2003/050188 WO2003101374A2 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters

Publications (1)

Publication Number Publication Date
NO20044903L true NO20044903L (no) 2005-02-25

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044903A NO20044903L (no) 2002-05-30 2004-11-10 Anvendelse av nye etonogestrel estere

Country Status (27)

Country Link
US (1) US20050222114A1 (de)
EP (1) EP1513588B1 (de)
JP (1) JP2005532336A (de)
KR (1) KR20050005507A (de)
CN (1) CN1655848A (de)
AR (1) AR040129A1 (de)
AT (1) ATE394140T1 (de)
AU (1) AU2003246740B2 (de)
BR (1) BR0311248A (de)
CA (1) CA2487293A1 (de)
DE (1) DE60320786D1 (de)
ES (1) ES2305498T3 (de)
HK (1) HK1072568A1 (de)
HR (1) HRP20041127A2 (de)
IL (1) IL165125A0 (de)
IS (1) IS7537A (de)
MX (1) MXPA04011798A (de)
NO (1) NO20044903L (de)
NZ (1) NZ536618A (de)
PE (1) PE20040042A1 (de)
PL (1) PL373295A1 (de)
RS (1) RS101004A (de)
RU (1) RU2322986C2 (de)
TW (1) TW200400041A (de)
UA (1) UA80703C2 (de)
WO (1) WO2003101374A2 (de)
ZA (1) ZA200409498B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
EP3697421B1 (de) * 2017-10-19 2024-04-17 Evestra, Inc. Länger wirkende progestin-prodrug-kontrazeptiva
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
EP4164743A2 (de) * 2020-06-11 2023-04-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Darstellung monomerer und oligomerer verbindungen als kontrazeptiva und therapien sowie verfahren zur herstellung und verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
AU692504B2 (en) * 1993-12-27 1998-06-11 Akzo Nobel N.V. Percutaneously absorbable preparation
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
PT1087986E (pt) * 1998-06-19 2002-08-30 Akzo Nobel Nv Undecanoato de 7alfa-metil-19-nortestosterona com actividade androgenica
AU4513099A (en) * 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Also Published As

Publication number Publication date
UA80703C2 (en) 2007-10-25
US20050222114A1 (en) 2005-10-06
PE20040042A1 (es) 2004-01-31
IL165125A0 (en) 2005-12-18
WO2003101374A3 (en) 2004-02-26
AR040129A1 (es) 2005-03-16
IS7537A (is) 2004-11-18
BR0311248A (pt) 2005-03-15
WO2003101374A2 (en) 2003-12-11
MXPA04011798A (es) 2005-03-31
CA2487293A1 (en) 2003-12-11
PL373295A1 (en) 2005-08-22
AU2003246740A1 (en) 2003-12-19
NZ536618A (en) 2007-06-29
RU2322986C2 (ru) 2008-04-27
RS101004A (en) 2006-10-27
TW200400041A (en) 2004-01-01
DE60320786D1 (de) 2008-06-19
HRP20041127A2 (en) 2005-02-28
EP1513588B1 (de) 2008-05-07
CN1655848A (zh) 2005-08-17
HK1072568A1 (en) 2005-09-02
RU2004138809A (ru) 2005-06-10
KR20050005507A (ko) 2005-01-13
JP2005532336A (ja) 2005-10-27
ZA200409498B (en) 2006-05-31
EP1513588A2 (de) 2005-03-16
ES2305498T3 (es) 2008-11-01
ATE394140T1 (de) 2008-05-15
AU2003246740B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
DK1490463T3 (da) Lav-transfedtsyrer til konfekture og fedtsammensætninger til bagning
DE60029956D1 (de) Amid-substituierte Imidazochinoline
NO20035632L (no) Selv-emulgerende formuleringer av kolesterylester-overforingsproteininhibitorer
FI20021947A (fi) Menetelmä triglyseridien rasvahappoketjukoostumuksen säätämiseksi sekä menetelmän käyttö
EE200300052A (et) Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid
IS5976A (is) Bensóheteróhringir og notkun theirra sem MEK-hemlar
NO20052229D0 (no) Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler
NO20041872L (no) Esterforbindelser og medisinsk anvendelse derav
CY1107641T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη
DK1292561T3 (da) Fremgangsmåde til fremstillingen af cyclopropylcarboxylsyreestere og -derivater
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
IS2421B (is) Nýir etónógestrel esterar
NO20044903L (no) Anvendelse av nye etonogestrel estere
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
DE60317214D1 (de) Kristallines gamma-lacton der17beta-hydroxy-7alpha-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carbonsäure
NO20014444L (no) Topisk appliserbare bioadhesive preparater samt fremgangsmåter for anvendelse og fremstilling derav
PT841933E (pt) Composicoes do inibidor bowman-birk para tratamento de doencas inflamatorias
NO20032054D0 (no) Fettsyreanaloger for behandling av inflammatoriske lidelser og autoimmune forstyrrelser
AU2003291634A1 (en) Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
DK1496884T3 (da) Blanding af et antithrombotisk middel med aspirin og anvendelse heraf til behandling af atherothrombotiske sygdomme
ITMI922657A0 (it) Composizione terapeutica per uso rettale a base di flunisolide e/o deirelativi esteri per il trattamento di disordini intestinali a carattere infiammatorio
ITMI991737A0 (it) Composizioni a rilascio controllato di paracetamolo
NO20031080L (no) Fettsyreanaloger for behandling av proliferative sykdommer
FR2818982B1 (fr) Inhibiteur specifique du systeme ubiquitine-proteasome et applications therapeutiques correspondantes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application